Achilles Therapeutics (ACHL): Price-to-Revenue Ratio

Symbol and logo of brand Achilles Therapeutics (ACHL)

Achilles Therapeutics (ACHL) leverages AI to create personalized medicines, gaining significant recognition from the scientific community. The volatility of the P/S ratio, where the parameter mark equals , highlights the risks of secondary offerings and the complexities of biomanufacturing. While high patent barriers and strict FDA oversight protect the company's developments, the asset's ultimate commercial viability will only be confirmed upon the release of final clinical trial results.

ACHL: Achilles Therapeutics plc P/S Multiple 07/04/2022 - 11/16/2026

Metric breakdowns and analytics for Achilles Tx (ACHL)

- current price and projected stock value:
General company analysis:ACHL - achillestx.com
Mass-produced product of Achilles Therapeutics PLC

For Achilles Therapeutics (ACHL), which operates in the emerging personalized cancer immunotherapy segment with colossal market potential, revenue is often stage-dependent. By analyzing the company's average P/S ratio, an investor determines the value of each unit of sales relative to market capitalization, which allows this chart to assess the asset's degree of overheating and the risks of capital impairment should business development forecasts deviate.